ANAB as reported
AnaptysBio, Inc. reported $232M of revenue over the trailing twelve months, +108% on the year before. 9 reported series are charted on this page, each one as filed.
$232M
Revenue, trailing twelve months · to Q1 2026 · +108% against the twelve months before
- Net Income
- −$27M
Net Income · −81% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $4.4M
Free Cash Flow · −104% year on year · trailing twelve months to Q1 2026
- Op Margin
- −36%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $232M | +108% | Q1 2026 |
| Net Income | −$27M | −81% | Q1 2026 |
| EPS | −$0.96 | −80% | Q1 2026 |
| Op Margin | −36% | n/a | Q1 2026 |
| Net Margin | −79% | n/a | Q1 2026 |
| ROE | 85% | n/a | Q1 2026 |
| ROA | −19% | n/a | Q1 2026 |
| ROIC | −767% | n/a | Q4 2020 · 21 quarters behind |
| Free Cash Flow | $4.4M | −104% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
AnaptysBio, Inc. (ANAB) - Revenue & ProfitRevenue & ProfitAnaptysBio, Inc. (ANAB)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Biotechnology
Ranks #102 of 145 by Smart Score